Chimera reduces the wet-lab validation cycle for gene-editing therapeutics by predicting off-target effects before synthesis. Spin from Monash biomedical research, the platform accelerates lead discovery for universities and biotech firms. Partners include institutes across Australia conducting rare-disease programmes.